Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Hardman Johnston Global Equity Cassandra A. Hardman | “We initiated a position in Elanco Animal Health, Inc. due to its unique potential to deliver double-digit revenue growth and strong earnings growth over the coming years. This is primarily driven by their solid pipeline of innovative products, including products for pain management for companion animals and parasiticides for companion animals and livestock. In addition, given the fragmented industry structure, the company has the potential to consolidate the industry by making acquisitions of other animal health competitors. Even without acquisitions, there is strong potential for gross margin expansion due to the shift from lower-margin products to newer products and improved execution from improved logistics. We see it as a rare opportunity to invest in a high-quality business at a compelling valuation. BSD Analysis: Elanco is still digesting past acquisitions, but the underlying animal health demand story remains intact. Pet humanization supports long-term growth, even if discretionary spending fluctuates. Margin pressure has forced operational discipline, which is slowly improving earnings quality. The livestock business adds diversification tied to global protein demand. Debt reduction remains the central task, but cash flow is stabilizing. Investors price Elanco as permanently impaired, ignoring normalization potential. R&D productivity is improving quietly. This is a repair story, not a broken one. If leverage comes down, equity upside follows.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Baron Health Care Fund Neal Kaufman | “We bought shares of Elanco Animal Health Incorporated, which operates in an industry supported by pet ownership growth and food safety trends. Elanco is at an inflection point as its innovation portfolio accelerates, targeting mid-single-digit revenue growth and double-digit EBITDA and EPS growth. Innovation revenue is expected to rise from 10.6% of sales in 2024 to over 22% in 2026. Management targets 200–350 basis points of EBITDA margin expansion and significant deleveraging by 2028. We believe management guidance may prove conservative. BSD Analysis: Elanco operates in a defensive healthcare niche where owners spend on animals even when they cut everything else. The problem has never been demand — it's been execution and balance-sheet baggage. Management is now focused on simplifying the portfolio and paying down debt rather than chasing growth illusions. The product base is broad, but innovation has lagged peers, putting pressure on pricing. That said, the installed base and global distribution still matter. Margins can recover if cost discipline sticks. This is not a high-growth animal health name. It's a repair-and-stabilize story with upside if expectations stay low. Elanco works only if management stays boring.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
